Neusoft Medical System’s PET Obtains U.S. FDA Authentication
This article was originally published in PharmAsia News
Executive Summary
Neusoft Medical System, a subsidiary of Neusoft Group, has received the go-ahead from U.S. FDA to market its positron emission computer tomography technology in the U.S. It represents China's first corporation capable of producing PET technology and marketing it globally. At present, China spends hundreds of million dollars each year importing medical equipment. About 70 percent of the local high-end medical device market is monopolized by MNCs; for instance, GE, Siemens and Philips have cornered the CT and MR sector. Neusoft Medical System's PET technology not only fills a gap in the country's high-end medical equipment manufacturing, but also marks a milestone in reforming the trade structure of the healthcare industry. The company will sell its first machine to the U.S. this July. (Click here for more - Chinese Language)
You may also be interested in...
Chinese Neusoft Medical System's 16 Multi-Slice CT Receives FDA Authentication
Neusoft Medical System has received FDA authentication for its NeuViz 16 multi-slice spiral computed tomography scanner, with the first machinebound for the U.S. This marks the firm's second breakthrough in the global high-end medical device market after launching its positron emission tomography product this May (PharmAsia News, June 8, 2009). NeuViz, developed jointly with Philips, integrates technologies from both companies. Neusoft Medical officials ascribe the year's achievements to its continuous input in new technology and products. Besides the CT devices, the company will progressively launch a superconducting MRI, a linear accelerator and a PET/CT in the near future. (Click here for more - Chinese Language)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.